Continuous IV infusion of MESNA can prevent hemorrhagic cystitis in HSCT and retain MESNA concentration in urine

Bone Marrow Transplant. 2015 Nov;50(11):1490-2. doi: 10.1038/bmt.2015.197. Epub 2015 Sep 14.
No abstract available

Publication types

  • Comparative Study
  • Letter
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acrolein / adverse effects
  • Acrolein / antagonists & inhibitors
  • Acrolein / urine
  • Adolescent
  • Adult
  • Aged
  • Allografts
  • Biotransformation
  • Child
  • Cyclophosphamide / adverse effects
  • Cyclophosphamide / pharmacokinetics
  • Cystitis / drug therapy
  • Cystitis / epidemiology
  • Cystitis / etiology
  • Cystitis / prevention & control*
  • Hematologic Neoplasms / therapy
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Hemorrhage / drug therapy
  • Hemorrhage / epidemiology
  • Hemorrhage / etiology
  • Hemorrhage / prevention & control*
  • Histocompatibility
  • Humans
  • Incidence
  • Infusions, Intravenous
  • Mesna / administration & dosage
  • Mesna / therapeutic use*
  • Mesna / urine
  • Middle Aged
  • Proportional Hazards Models
  • Prospective Studies
  • Retrospective Studies
  • Transplantation Conditioning / adverse effects
  • Transplantation Conditioning / methods
  • Young Adult

Substances

  • Acrolein
  • Cyclophosphamide
  • Mesna